| REVIEW ARTICLE |
|
| Year : 2017 | Volume
: 15
| Issue : 3 | Page : 169-176 |
|
|
Oral antidiabetic agents: Recently available novel oral antidiabetic agents in India: A clinical review
Nitin Kapoor1, Nihal Thomas2
1 Department of Endocrinology, Diabetes and Metabolism, Christian Medical College and Hospital, Vellore, India; Non communicable Diseases Unit, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia
2 Department of Endocrinology, Diabetes and Metabolism, Christian Medical College and Hospital, Vellore, India
Correspondence Address:
Nitin Kapoor
Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore - 632 004, Tamil Nadu, India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/cmi.cmi_39_17
|
|
|
Oral anti-diabetic agents form an important therapeutic strategy in the management of diabetes, after lifestyle modification. There are several new agents available, like dipeptidyl peptidase 4 (DPP4) inhibitors and sodium- glucose cotransporter 2 (SGLT2) inhibitors have been approved for use as monotherapy when diet and exercise are inadequate and when metformin is not tolerated, and can also be utilized as an add on to other glucose-lowering agents, including insulin. The therapeutic, pharmacokinetic and safety profiles of these agents are different from the older agents. Hydroxychloroquine (hcq) and bromocriptine have been recently cleared for use and show beneficial effects in control of blood glucose and HbA1C levels.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
